Is Mounjaro better than Ozempic for PCOS?

No head-to-head trial has compared them in PCOS, so any answer is an indirect comparison. In obesity trials, tirzepatide 15 mg produced about -20.9% body weight at 72 weeks (SURMOUNT-1, NEJM 2022) versus about -14.9% for semaglutide 2.4 mg at 68 weeks (STEP 1, NEJM 2021) — those populations were not selected for PCOS and cycles were not an outcome. In PCOS specifically, the only randomised data for either drug on cycles come from a 60-participant, 16-week open-label trial of tirzepatide 5 mg added to metformin (Yang et al., Diabetes Obesity and Metabolism 2026). Semaglutide has the longer pharmacovigilance track record. Both are off-label for PCOS.

Is tirzepatide covered by insurance for PCOS in the US?

No. As of May 2026, neither the FDA nor any major insurer covers tirzepatide specifically for PCOS. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for obesity management (BMI ≥ 30, or ≥ 27 with comorbidity). PCOS alone does not qualify for coverage. Off-label use means out-of-pocket cost: approximately $1,000-1,400/month without insurance. Eli Lilly's savings program can reduce this to ~$550/month for eligible commercially insured patients.

Can I take Mounjaro if I want to get pregnant?

No — tirzepatide is contraindicated during pregnancy. Preclinical animal studies showed fetal toxicity at doses equivalent to human doses. Stop Mounjaro or Zepbound at least 2 months before attempting conception (tirzepatide half-life is approximately 5 days, with accumulation over 4-5 weeks). Effective contraception is mandatory throughout treatment. Paradoxically, tirzepatide can restore ovulation in previously anovulatory women, increasing the risk of unplanned pregnancy — so contraception is critical from day one.

How long before seeing effects on my cycles with Mounjaro?

Metabolic effects (improved insulin resistance, reduced androgens) typically appear within 4-12 weeks, and clinicians generally look for cycle changes between 3 and 6 months. Be aware that the evidence base here is thin: the only randomised trial reporting cycles with tirzepatide in PCOS ran 16 weeks in 60 women and found cycle recovery more frequent when tirzepatide 5 mg was added to metformin than with metformin alone (p = 0.013), without publishing a response rate. The dedicated trial built around menstrual regularity (PERIODS, NCT07326111) is still recruiting. Individual responses vary significantly.

What tests should I have before starting Mounjaro?

Before starting tirzepatide, recommended baseline workup includes: fasting glucose + HbA1c, full lipid panel, liver function tests (AST/ALT), baseline serum lipase, TSH and thyroid examination, androgen panel (total and free testosterone, DHEAS), HOMA-IR (fasting glucose + fasting insulin), CBC, creatinine with eGFR. Personal and family history of medullary thyroid carcinoma or MEN2 must be specifically asked about — these are absolute contraindications.

Is there a cheaper alternative to tirzepatide for PCOS?

Yes. Metformin ($4-15/month generic) remains the first-line reference for PCOS with insulin resistance. Myo-inositol ($25-60/month, OTC) is a well-tolerated natural option. Semaglutide (Ozempic/Wegovy, ~$800-1,500/month or ~$25/month with savings cards) is less expensive than tirzepatide while having well-documented efficacy in PCOS. Tirzepatide is best justified when other options have failed or are insufficient, and when significant weight loss is a primary therapeutic goal.

Guide · Updated October 8, 2026 · pmos-pcos.com team

Mounjaro & Zepbound for PCOS — Tirzepatide, GLP-1+GIP Dual Agonist (2026)

Tirzepatide (Mounjaro, Zepbound) produces the largest weight loss of any approved obesity medication — -20.9% at 72 weeks on the 15 mg dose versus -3.1% on placebo (SURMOUNT-1, NEJM 2022). But that trial was not run in PCOS, and as of October 2026 no phase-3 trial of tirzepatide dedicated to PCOS has been published. Here is what the evidence does and does not say, what it costs off-label in the US, and what to settle before discussing it with your doctor.

Information, not a diagnosis. This page provides general guidance. It does not constitute a diagnosis and does not replace a personalised medical consultation.

What is tirzepatide?

Tirzepatide is a once-weekly injectable medication developed by Eli Lilly, belonging to a novel pharmacological class: dual GLP-1 and GIP receptor agonists (glucose-dependent insulinotropic polypeptide). Where semaglutide (Ozempic, Wegovy) acts exclusively on the GLP-1 receptor, tirzepatide simultaneously activates two distinct incretin receptors, producing more pronounced metabolic effects than mono-agonist GLP-1 agents.

GIP is an intestinal hormone released after meals that, like GLP-1, stimulates glucose-dependent insulin secretion. GIP also acts directly on adipose tissue and, in combination with GLP-1 receptor activation, appears to generate a stronger satiety signal than either pathway alone. This dual mechanism explains the superior weight loss observed with tirzepatide vs semaglutide across multiple trials.

For women with PCOS, the dual GLP-1+GIP targeting is especially relevant: insulin resistance (present in 50-80% of PCOS cases, including lean women) is addressed through both pathways simultaneously, compensatory hyperinsulinemia falls, and LH-stimulated androgen production by the ovaries — directly driven by insulin — is reduced. Sources: Nauck & D'Alessio, Nature Reviews Drug Discovery 2022.

Mounjaro vs Zepbound: What's the difference?

Mounjaro and Zepbound are the exact same molecule: tirzepatide. The difference is purely regulatory and commercial — the same model used by Novo Nordisk with Ozempic (diabetes) and Wegovy (obesity).

Mounjaro — approved by the FDA for type 2 diabetes management. Available in doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. FDA approval: May 2022.
Zepbound — approved by the FDA in November 2023 for chronic weight management in adults with BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (including hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). Same doses as Mounjaro.

In practice, for a woman with PCOS who also has obesity meeting Zepbound criteria (BMI ≥ 30 or ≥ 27 + comorbidity), a prescription for Zepbound for the obesity indication is on-label — even though the PCOS indication specifically remains off-label. For PCOS alone without qualifying obesity or diabetes, any prescription remains off-label.

What the evidence actually shows (October 2026)

This is the part most pages get wrong, so it is worth being precise. There is no large dedicated phase-3 trial of tirzepatide in PCOS. Three separate bodies of evidence are routinely blurred together:

Obesity trials (not PCOS). SURMOUNT-1 randomised 2,539 adults with obesity and without diabetes to tirzepatide or placebo for 72 weeks: -20.9% body weight on 15 mg, -19.5% on 10 mg, -15.0% on 5 mg, versus -3.1% on placebo (Jastreboff et al., NEJM 2022;387:205-216). Cycles, ovulation and androgens were not measured. This is where the “15-22% weight loss” figure comes from.
One randomised trial in PCOS, small and short. Sixty overweight or obese Chinese women with PCOS were randomised to metformin 1,000 mg twice daily alone, or metformin plus tirzepatide 5 mg weekly, for 16 weeks: weight fell 10.4 ± 3.5 kg in the combination arm versus 1.7 ± 2.5 kg on metformin alone (BMI -4.12 vs -0.68 kg/m²), with significantly more frequent menstrual cycle recovery (p = 0.013) and a higher total pregnancy rate (p = 0.014) — Yang et al., Diabetes, Obesity and Metabolism 2026. Open-label, single centre, 16 weeks, low dose: a first signal, not a settled answer.
Real-world data in PCOS. In a UK cohort of 4,241 women with self-reported PCOS using tirzepatide through a digital weight service, mean weight loss at 10 months was -19.40% (95% CI -22.38 to -16.42), statistically no different from women without PCOS (-18.74%, p = 0.68) — Clift et al., Journal of the Endocrine Society 2026. Caveats: PCOS was self-reported, only 40 women with PCOS were still in follow-up at 10 months, and no reproductive outcome was reported.

What is coming. PERIODS (NCT07326111), a phase-4 placebo-controlled trial of 198 participants run by the University of Bonn, has been recruiting since December 2025. Its primary outcome is whether menstrual regularity improves — the first trial designed around the reproductive question rather than weight. No results yet.

How to read a confident number. If you see a precise claim such as “restores cycles in 65% of women with PCOS”, ask which trial it comes from. As of October 2026 no published trial supports a figure of that kind.

Expected results for a woman with PCOS

Extrapolating from the obesity trials and the small PCOS data above, here is a reasonable — and deliberately cautious — expectation for a woman with PCOS and obesity, subject to individual response:

Weight loss: on average 15-22% of initial body weight over 12-18 months in obesity trials, and a comparable figure in the PCOS real-world cohort — greater than achieved with semaglutide (-13-15%) or metformin (-2-5%).
Cycle regularization: more likely than without treatment, on the strength of one small randomised trial, and generally looked for within 3-6 months. No reliable response rate can be quoted. Ovulation improvement often precedes complete cycle normalization.
Hirsutism reduction: visible clinical effect after 6-12 months, linked to the reduction in total and free testosterone. Excess hair growth diminishes gradually.
Fertility improvement: indirectly, via ovulation restoration. Warning: this increases the risk of unplanned pregnancy in women who believed they were subfertile. Effective contraception is essential throughout treatment.
Timeline: metabolic effects (HOMA-IR, glucose): 4-8 weeks. Cycle effects: 3-6 months. Androgen and hirsutism effects: 6-12 months.

Mounjaro vs Ozempic/Wegovy for PCOS

Available 2026 data allow a meaningful comparison, although no head-to-head trial specifically in PCOS has been published yet.

Criterion	Tirzepatide (Mounjaro/Zepbound)	Semaglutide (Ozempic/Wegovy)
Mechanism	Dual GLP-1 + GIP	GLP-1 only
Weight loss in PCOS	-19.4% at 10 months (real-world cohort, Clift 2026)	-13.7% (observational data)
Cycle restoration	More frequent than metformin alone (p = 0.013); no response rate published	35-55% (observational studies)
Androgen reduction	Not reported in the PCOS trial	-15 to -20% (variable data)
Evidence level in PCOS	One small open-label RCT (n = 60, 16 weeks) + real-world cohort; dedicated trial PERIODS recruiting	Observational studies + subgroup analyses
Safety track record	Shorter (newer molecule)	Longer (FDA approval 2017 for T2D)
US price (out-of-pocket)	~$1,000-1,400/month; ~$550 with Lilly savings card	~$800-1,500/month; ~$25 with Novo savings card

A nuanced recommendation: if significant weight loss is the priority and cost is not a barrier, tirzepatide is today the best-documented option in PCOS with the highest level of evidence. If cost or the longer pharmacovigilance record of semaglutide are important considerations, Ozempic/Wegovy remains a solid alternative. The decision must account for individual context, fertility plans, and the prescribing physician's judgment.

US pricing, availability, and access

Understanding the US cost landscape is essential for planning:

Mounjaro (diabetes indication): list price approximately $1,000-1,100/month. Insurance coverage for type 2 diabetes indication where applicable.
Zepbound (obesity indication): list price approximately $1,060-1,400/month depending on dose. Insurance coverage under obesity indication where plan covers it (many commercial plans and Medicare Part D have coverage gaps for anti-obesity medications).
For PCOS specifically (off-label): typically not covered by insurance. Out-of-pocket costs apply. If the patient also meets BMI criteria for Zepbound, coverage for the obesity indication may be accessible separately from the PCOS context.
Eli Lilly savings program: Zepbound Savings Card can reduce monthly cost to ~$550 for eligible commercially insured patients. Lilly Cares Foundation offers patient assistance for uninsured patients meeting income criteria. Check zepbound.lilly.com/savings for current eligibility.
Prescription required: always. Off-label use requires physician-documented informed consent. Compounded tirzepatide from 503B pharmacies may be available but quality control concerns exist — discuss with your prescriber.

Side effects specific to PCOS patients

No PCOS-specific safety dataset exists for tirzepatide. What follows is the side effect profile of the GLP-1/GIP class as documented in the obesity and diabetes trials, with the points that matter most in PCOS flagged:

Common (>10% of users):

Nausea and vomiting: reported in 28-35% of participants, primarily at treatment initiation and dose escalation steps. Typically subsides within 4-8 weeks. Strategies: small meals, avoid high-fat foods, inject in the evening.
Diarrhea / constipation: related to reduced gastric motility, generally transient.

Less common (1-10%):

Pancreatitis: estimated risk ~0.1% — rare but serious. Monitor if intense upper abdominal pain with back radiation develops. Check serum lipase.
Cholelithiasis (gallstones): rapid weight loss promotes gallstone formation. Consider abdominal ultrasound at 6 months in high-risk patients.

Absolute contraindications:

Thyroid (medullary carcinoma): signal observed in rodent studies at supratherapeutic doses — not confirmed in human epidemiological studies. Contraindication maintained if personal or family history of medullary thyroid carcinoma or MEN2.
Pregnancy and breastfeeding: stop at least 2 months before attempting conception. Effective contraception required throughout treatment.
Hypoglycemia risk: low in monotherapy (glucose-dependent insulin secretion), but increased risk when combined with sulfonylureas or insulin.

How to start safely under medical supervision

Tirzepatide follows a progressive titration protocol over 20 weeks to minimize gastrointestinal side effects:

Weeks 1-4: 2.5 mg/week
Weeks 5-8: 5 mg/week
Weeks 9-12: 7.5 mg/week
Weeks 13-16: 10 mg/week
Weeks 17-20: 12.5 mg/week (if well tolerated)
Maximum dose: 15 mg/week

Recommended medical follow-up: appointment at 1 month to assess tolerability, then every 3 months (glucose panel, liver function, serum lipase if digestive symptoms, androgen panel at 6 months). Cycle and ovulation monitoring (basal body temperature, pelvic ultrasound) is recommended for women with PCOS.

Frequently asked questions

Is Mounjaro better than Ozempic for PCOS?: No head-to-head trial has compared them in PCOS, so any answer is an indirect comparison. In obesity trials, tirzepatide 15 mg produced about -20.9% body weight at 72 weeks (SURMOUNT-1, NEJM 2022) versus about -14.9% for semaglutide 2.4 mg at 68 weeks (STEP 1, NEJM 2021) — those populations were not selected for PCOS and cycles were not an outcome. In PCOS specifically, the only randomised data for either drug on cycles come from a 60-participant, 16-week open-label trial of tirzepatide 5 mg added to metformin (Yang et al., Diabetes Obesity and Metabolism 2026). Semaglutide has the longer pharmacovigilance track record. Both are off-label for PCOS.
Is tirzepatide covered by insurance for PCOS in the US?: No. As of May 2026, neither the FDA nor any major insurer covers tirzepatide specifically for PCOS. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for obesity management (BMI ≥ 30, or ≥ 27 with comorbidity). PCOS alone does not qualify for coverage. Off-label use means out-of-pocket cost: approximately $1,000-1,400/month without insurance. Eli Lilly's savings program can reduce this to ~$550/month for eligible commercially insured patients.
Can I take Mounjaro if I want to get pregnant?: No — tirzepatide is contraindicated during pregnancy. Preclinical animal studies showed fetal toxicity at doses equivalent to human doses. Stop Mounjaro or Zepbound at least 2 months before attempting conception (tirzepatide half-life is approximately 5 days, with accumulation over 4-5 weeks). Effective contraception is mandatory throughout treatment. Paradoxically, tirzepatide can restore ovulation in previously anovulatory women, increasing the risk of unplanned pregnancy — so contraception is critical from day one.
How long before seeing effects on my cycles with Mounjaro?: Metabolic effects (improved insulin resistance, reduced androgens) typically appear within 4-12 weeks, and clinicians generally look for cycle changes between 3 and 6 months. Be aware that the evidence base here is thin: the only randomised trial reporting cycles with tirzepatide in PCOS ran 16 weeks in 60 women and found cycle recovery more frequent when tirzepatide 5 mg was added to metformin than with metformin alone (p = 0.013), without publishing a response rate. The dedicated trial built around menstrual regularity (PERIODS, NCT07326111) is still recruiting. Individual responses vary significantly.
What tests should I have before starting Mounjaro?: Before starting tirzepatide, recommended baseline workup includes: fasting glucose + HbA1c, full lipid panel, liver function tests (AST/ALT), baseline serum lipase, TSH and thyroid examination, androgen panel (total and free testosterone, DHEAS), HOMA-IR (fasting glucose + fasting insulin), CBC, creatinine with eGFR. Personal and family history of medullary thyroid carcinoma or MEN2 must be specifically asked about — these are absolute contraindications.
Is there a cheaper alternative to tirzepatide for PCOS?: Yes. Metformin ($4-15/month generic) remains the first-line reference for PCOS with insulin resistance. Myo-inositol ($25-60/month, OTC) is a well-tolerated natural option. Semaglutide (Ozempic/Wegovy, ~$800-1,500/month or ~$25/month with savings cards) is less expensive than tirzepatide while having well-documented efficacy in PCOS. Tirzepatide is best justified when other options have failed or are insufficient, and when significant weight loss is a primary therapeutic goal.

Key sources

Medical disclaimer: This page is for informational purposes only. Mounjaro and Zepbound (tirzepatide) are prescription-only medications. Their use in PCOS is off-label. Do not start, stop, or modify any prescription medication without consulting a qualified endocrinologist or reproductive endocrinologist.